Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Genomic Profiling Showcase will provide a 15-30 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
Confirmed Presenting Companies:
Speaker Profile
M.D., Senior Vice President, Medical, Castle Biosciences
Biography
Dr. Matthew Goldberg is a board-certified dermatologist and dermatopathologist. Prior to joining Castle, Dr. Goldberg was an Assistant Professor in Dermatology and Pathology at the Icahn School of Medicine at Mount Sinai in New York and retains his affiliation as an Assistant Clinical Professor of Dermatology. Prior to joining the Mount Sinai faculty, he directed Dermatopathology education for the MedStar Georgetown Washington Hospital Center dermatology residency program. Dr. Goldberg has a background in translational melanoma research and received the Dermatology Foundation Dermatopathology Research Career Development Award for research in melanoma epigenetics.
Talk
AI unlocks the clinical utility of spatialomics
Spatialomics provide robust data to interrogate multiple pathways of disease progression simultaneously. Using AI to interpret these pathways can unlock new understanding that has the potential to profoundly improve patient management. This talk will explore how synergies between AI and spatialomics have been validated to predict progression to esophageal cancer in Barretts esophagus patients.
Genomic Profiling Showcase:
Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions.
Speaker Profile
Ph.D., PHARMD, Deputy CEO &CSO, ALCEDIAG
Biography
Dinah Weissmann is Founder and CSO at Alcediag, a biotech company dedicated to the development of innovative diagnostics based on epigenetic biomarkers. Dinah is also co-Director of a public-private laboratory dedicated to the understanding the molecular basis of complex diseases. Her research field, mainly in neurosciences is dedicated to improve the conditions of patients suffering from mental disorders. Her last focus is the understanding of epigenetic mechanism impact on mood disorders and the development of blood tests to diagnose psychiatric conditions like depression and bipolar disorder. Her goal is to innovate to improve the patients quality of life .
Talk
RNA editing blood biomarkers for bipolar diagnosis
The differential diagnosis of bipolar disorder and MDD is challenging, bipolar patients remain undiagnosed for years. Alcediag has developed blood biomarkers for mood disorder based on RNA editing and artificial intelligence. This panel of biomarkers was tested in two independent cohorts and show high performance in diagnosing bipolar patients.
Genomic Profiling Showcase:
ALCEDIAG
ALCEDIAG is an innovative diagnostic company specializing in the development and commercialization of blood tests, monitoring solutions, and companion diagnostics, primarily for mental health. These offerings are based upon the company’s distinctive expertise in epigenetics, RNA, and Artificial Intelligence, complemented by neurosciences and psychiatry.
Speaker Profile
Ph.D., Chief Scientific Officer, Precede Biosciences
Biography
Dr. J. Carl Barrett is a renowned professional in the field of translational medicine and diagnostics with over 17 years of experience in drug development and technology advancement. In his previous role as the Vice President and Head of Oncology Translational Medicine at AstraZeneca Pharmaceuticals, he led a global team, spearheading biomarker strategy and translational sciences to support oncology drug development. Dr. Barrett's career also includes leadership positions at Novartis Institutes for BioMedical Research and the National Cancer Institute. He has made significant contributions to the field, with over 600 publications to his name and a reputation for mentoring future leaders in the pharmaceutical and biomedical sectors. Driven by a passion for lifelong learning and effective communication, he continues to shape the landscape of healthcare innovation.
Talk
Comprehensive Epigenomic Profiling from Plasma to Inform Therapy Selection
Precede Bio's novel liquid biopsy platform interrogates genome-wide transcriptional biology from 1 mL of plasma through analysis of DNA associated with histone marks of active transcription. This comprehensive multi-analyte epigenomic profiling approach has the potential to investigate the transcriptional status of individual genes and genome-wide biology that is correlated or anti-correlated with targets of interest.
Genomic Profiling Showcase:
Precede Biosciences
Precede Bio is impacting the development and use of precision medicines with a first-in-classcomprehensive epigenomic liquid biopsy platformdesigned to reveal the fundamental biology behind disease at any given moment so that researchers and clinicians can better target medicines to the right patients.
Speaker Profile
M.D., Ph.D., Vice President, Genomic Health, 23andMe
Biography
Dr. Noura Abul-Husn leads 23andMe's clinical strategy to integrate consumer genetics into healthcare. In addition to her leadership role at 23andMe, she is an Associate Professor at the Icahn School of Medicine at Mount Sinai. Dr. Abul-Husn is a physician scientist and expert in personalized healthcare and genomic medicine. She was the founding Chief of the Division of Genomic Medicine and Clinical Director of the Institute for Genomic Health at Mount Sinai, overseeing multidisciplinary teams of clinicians and researchers to spearhead genomic research, education, and care delivery innovation. Prior to that, she served as Director of Translational Genetics at the Regeneron Genetics Center. She is the recipient of numerous awards and has spoken and published extensively on her research spanning genomic discovery, genomic medicine, and health equity. Dr. Abul-Husn is a double board-certified Internist and Medical Geneticist. She completed her MD, PhD, and residency at Mount Sinai in New York.
Talk
Genetics: The Key to Personalized, Preventive Health
With so many individuals motivated to live longer, healthier lives, many still dont understand the power of genetics when it comes to preventive health. 23andMe offers direct-to-consumer genetic insights not readily available through traditional healthcare. Having personalized insights into ones own health risks empowers individuals to take the right actions to stay healthy, longer.
Genomic Profiling Showcase:
23andMe
23andMe is a genetics-led consumer healthcare company empowering a healthier future.
Speaker Profile
M.D., Ph.D., Chief Scientific Officer & Vice President, BioAro
Biography
Precision health OMICs Innovation translational clinical research specialist with extensive experience in Operational leadership to large Provincial University programs SMEs for:1.Creation of an inclusive Ecosystem of Clinical Research Innovation Entrepreneurship2.Translation commercialization of innovative research into clinicmarket3.Strategic initiatives to develop Cutting-edge infrastructure HQP training programs 4.Integration of AIML Quantum tools and Big data into practise 5.Indigenousunderrepresented community outreach for research engagement. Raja is the Chief Scientific Officer, BioAro Inc, (and Vice President, Research Innovation, CardiAI Inc.). Earlier he was with the Faculty of Medicine Dentistry University of Alberta, as Director, Alberta Prostate Cancer Network (APCaRI), Director, Alberta Health Network (AAHN) and as Director, Genome Alberta (Alberta Epigenetics Network), Alberta Canada. Trained as a Physician, Raja obtained his PhD in Cardiovascular Sciences. He has published extensively in high impact peer-reviewed medical journals and written book chapters in cardiac research, genomics, epigenomics and microbiome investigations.
Talk
Unveiling Power of AI with PanOmiQ Analysis
AI and ML powered end to end genomic analysis is critical for providing precision medicine based support to our patients. PanOmiQ is the first software platform to do so.
Genomic Profiling Showcase:
BioAro Inc.
BioAro Inc. is a Calgary based Canadian company providing personalized medicine services to patients through development of AI based software platforms for analyiss and integration of multi-OMICS data into clinical care
Speaker Profile
Chief Healthspan Officer, BioAro
Biography
Raman Kapoor, a Registered Dietitian, entrepreneur, philanthropist, and mother, is committed to advancing healthier communities through prevention and personalized care. As Chief Healthspan Officer at BioAro Inc., she leads efforts to integrate precision medicine into daily life, empowering individuals to take control of their health by tailoring solutions to their lifestyle, genetics, and microbiome.Raman is also the founder of NEA Precision Skin, where science and innovation come together to promote skin health as part of overall well-being. Additionally, she co-founded a wellness-focused charity that has positively impacted over 25,000 lives.With over 20 years of professional and volunteer experience, Raman emphasizes education and capacity building to inspire healthier, more confident living. Recognized with the Women of Inspiration Award for her contributions, she continues to champion healthspan optimization, helping individuals unlock their full potential for longevity and vitality.
Talk
MultiOmics and AI Unlock Peak Sports Performance
TheBioSport combines MultiOmics analysis and AI to revolutionize athletic performance. By leveraging genomics, microbiomics, and metabolomics, it provides personalized insights into an athletes physiology. AI-driven strategies optimize training, recovery, and nutrition, helping athletes achieve peak performance while reducing injury risk. This cutting-edge approach empowers excellence on and off the field.
Genomic Profiling Showcase:
BioAro
BioAro is a leading innovator in the fields of biotechnology, science, longevity and healthspan.
Each individual is unique, with a complex interplay of DNA, metabolism, microbiome, and lifestyle. BioAro has developed an ecosystem of tools to harness these complexities.
Speaker Profile
M.D., Ph.D., Professor of Medicine, MD Anderson Cancer Ctr.
Biography
Dr. Tsimberidou is a Professor of Medical Oncology at MD Anderson. She has designed highly innovative clinical trials that have changed the standard of oncology practice. She pioneered the personalized medicine program for advanced cancer that improved patient care and established a model for clinical trials at other institutions, nationally and internationally. She led multiple clinical trials and has published 350 articles. She has been invited to present her work as a keynote speaker at national and international conferences. She has received many awards, including an ASCO Career Development Award. She chaired ASCO's Clinical Research Committee (2016-2017) and she was appointed as a member of other committees. Because of her accomplishments in personalized medicine, she was elected a Fellow of the American Association for the Advancement of Science (FAAAS) and for her contributions to ASCO, she received the designation of Fellow of ASCO (FASCO). She is a Katherine Russell Dixie Distinguished Endowed Professor.
Talk
Innovations in Precision Oncology: From Genomics to Therapy.
The application of artificial intelligence (AI) and machine learning (ML) has accelerated advancements in Precision Oncology. AIML techniques in genomic, pathological, and radiomic evaluation enable a deep, fast, and precise understanding of tumor biology and have the potential to significantly accelerate the development of personalized therapies for patients with cancer.
Genomic Profiling Showcase:
MD Anderson Cancer Center
The mission of the University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate/graduate students, trainees, professionals, employees and the public.
